MARKET

DXR

DXR

DAXOR CORP
AMEX

Real-time Quotes | Nasdaq Last Sale

13.60
+0.10
+0.74%
Closed 16:00 11/25 EST
OPEN
13.50
PREV CLOSE
13.50
HIGH
14.15
LOW
13.50
VOLUME
1.41K
TURNOVER
--
52 WEEK HIGH
24.08
52 WEEK LOW
7.85
MARKET CAP
52.89M
P/E (TTM)
-11.7130
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
THIRD HOSPITAL JOINS MULTICENTER COVID-19 BVA-100® BLOOD TEST STUDY
NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that Wake Forest Baptist Health will participate in an ongoing trial to treat patients hospitalized with COVID-19 utilizing Daxor's BVA-100 (Blood Volume Analyzer, "BVA") technology. Wake Forest School of Medicine is based in Winston-Salem, North Carolina, and is set to enroll patients under the leadership of Ashish K. Khanna, MD. “Having such a prestigious academic and research center such as Wake Forest join the ongoing multi-center trial alongside Oregon Health & Science University and NYU Langone Health highlights the importance of BVA technology in helping clinicians understand COVID-based volume derangements to improve care and outcomes,” said Michael Feldschuh, CEO and President of Daxor. “SARS-CoV-2 attacks the endothelium causing volume derangement and capillary distress. Daxor’s BVA test is the first and only diagnostic test cleared by FDA that offers insights into patients’ capillary leak rate via its albumin tracer in addition to 98% accurate measure of plasma and red cell volume. Elevated leak rate has been shown as a prognostic marker associated with higher mortality, knowledge of it and volume status can be used to triage patients, guide treatment, and measure response to interventions.”“We hope this important trial will help inform volume status and provide crucial insights into COVID-19 pathophysiology,” said Dr. Khanna, Associate Professor in Anesthesiology, Section Head for Research, Section in Critical Care Medicine, Wake Forest School of Medicine.Daxor is the global leader in blood volume measurement technology, utilized by major hospitals in the United States. In a randomized control trial (RCT) published in the journal Shock, the BVA-100® has shown to reduce ICU mortality by 66% (P=0.03) and reduce ventilator days in patients suffering predominantly from acute respiratory distress syndrome and septic shock. Additionally, the analysis showed 44% of BVA test results led to a change in treatment strategy (P=0.004) that care teams would not have performed absent the data from the BVA volume status measure.About Daxor CorporationDaxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.Forward-Looking StatementsCertain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Investor Relations Contact: Bret Shapiro Sr. Managing Partner, CORE IR 516-222-2560 brets@coreir.com
GlobeNewswire · 11/19 13:30
OREGON HEALTH & SCIENCE UNIVERSITY JOINS MULTICENTER COVID-19 BVA-100® STUDY
COVID-19 Investigation Continues at OHSU to Study Hospitalized Patients Utilizing Daxor’s Blood Volume Analysis TechnologyNEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that Oregon Health & Science University ("OHSU"), the state’s only comprehensive public academic health center, joins NYU Langone Health as the second site to participate in a trial to treat patients hospitalized with COVID-19 utilizing Daxor's BVA-100 (Blood Volume Analyzer, "BVA") technology. OHSU is based in Portland, Oregon, and is set to begin enrolling patients under the leadership of Martin A. Schreiber, M.D."We are thrilled to have OHSU, one of the leading academic and research centers in the United States, join NYU Langone Health in this critical multicenter COVID-19 BVA trial," said Michael Feldschuh, CEO and President of Daxor. “The exact quantification of total blood, red cell and plasma volume and knowledge of capillary status are unique to Daxor's BVA technology and provides clinicians precise volume measurement that is superior to commonly used indirect estimates. We believe our test can have a significant impact on patient triage, outcomes and optimal use of resources.”The BVA is the first and only diagnostic test cleared by the FDA that directly measures capillary permeability via its albumin tracer, a capability that provides crucial insight into COVID-19 pathophysiology. A persistently elevated leak rate is a prognostic marker associated with higher mortality, which can be used to triage patients, guide treatment, and measure response to interventions. This study aims to show the implications of COVID as an endothelial disease utilizing this unique measure."In light of the fact that the SARS-CoV-2 virus attacks the endothelium causing increasing permeability, this technology could help determine volume status in these patients as well as quantifying the 3rd spacing rate," said Dr. Schreiber, Professor of Surgery, Division of Trauma, Critical Care and Acute Care Surgery, OHSU School of Medicine.In a randomized control trial (RCT) published in 2011 in the journal Shock, the BVA-100® has shown to reduce ICU mortality by 66% and reduce ventilator days in patients suffering predominantly from acute respiratory distress syndrome and septic shock. Additionally, the analysis showed 44% of BVA test results led to a change in treatment strategy (P=0.004) that care teams would not have performed absent the data from the BVA volume status measure.About Daxor CorporationDaxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information, please visit our website at Daxor.com.Forward-Looking StatementsCertain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Investor Relations Contact: Bret Shapiro Sr. Managing Partner, CORE IR 516-222-2560 brets@coreir.com
GlobeNewswire · 10/29 13:30
Daxor to Present at H.C. Wainwright 22nd Annual Global Investment Conference
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor’s President & Chief Executive Officer, will present
GlobeNewswire · 09/10 13:30
Daxor Corporation reports a 29.6 Percent Rise in Sales Revenue for Six Months in Filing of Form N-CSR for June 30, 2020
NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, filed a Form N-CSR disclosing its schedule of portfolio holdings as of June 30, 2020. Daxor reported an increase in revenue of 29.6% in the Company’s diagnostic division representing strong strides in the commercialization of its BVA-100 Blood Volume Analyzer. Further sales are expected for the remainder of the year following the Company’s recent distribution agreement with American Medical Depot, a distributor to U.S. Government facilities such as the Veteran’s Administration. Furthermore, the Company was awarded a $1.1 million dollar contract with the Department of Defense for blood volume analyzers intended for combat casualty use.Management is pleased to report that as of July 31, 2020 the company held net assets of $13,541,192 or $3.36 per share, a result achieved by a combination of market recovery, dividends, hedging proceeds, sales, and capital raise.“Sales continue to excel in key areas despite the challenges of COVID-19,” said Michael Feldschuh, CEO and President of Daxor. “Recent additions of new Board members and key personnel to focus on commercialization, engineering, and research are drivers, including the initiation of a multi-center prospective trial in COVID-19 patients and patient enrollment in a randomized control trial for heart failure management at Duke Hospital system.”Form N-CSR for the period ended June 30, 2020 is available on the Securities and Exchange Commission (“SEC”) website at www.sec.gov and on the Company’s website at Daxor.comAbout Daxor CorporationDaxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information, please visit our website at Daxor.comForward-Looking StatementsCertain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Investor Relations Contact: Bret Shapiro Sr. Managing Partner, CORE IR 516-222-2560 brets@coreir.com
GlobeNewswire · 08/24 13:30
Daxor Announces a 29.6% Increase in Revenue From its Diagnostic Division for 1H 2020
Benzinga · 08/24 12:37
NKLA, IBIO, PETS and TNXP among midday movers
Seeking Alpha - Article · 07/20 16:39
Daxor Corporation Announces Pricing of $7.0 Million Registered Direct Offering
GlobeNewswire · 07/20 14:09
Daxor prices $7M direct equity offering
Seeking Alpha - Article · 07/20 13:33
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DXR. Analyze the recent business situations of DAXOR CORP through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DXR stock price target is 21.00 with a high estimate of 22.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 4
Institutional Holdings: 79.82K
% Owned: 2.05%
Shares Outstanding: 3.89M
TypeInstitutionsShares
Increased
3
6.30K
New
0
0
Decreased
1
2.00K
Sold Out
3
74.58K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.24%
Healthcare Equipment & Supplies
-0.25%
Key Executives
Chairman/President/Chief Executive Officer/Director
Michael Feldschuh
Chief Financial Officer
Robert Michel
Chief Scientific Officer/Director
Jonathan Feldschuh
Director
Henry Cremisi
Director
Edward Feuer
Independent Director
Joy Goudie
Independent Director
James Lombard
Independent Director
Robert Willens
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
12/28/2017
Dividend USD 0.03
01/05/2018
11/18/2016
Dividend USD 0.03
12/20/2016
12/09/2015
Dividend USD 0.04
12/18/2015
11/17/2014
Dividend USD 0.03
12/04/2014
11/15/2013
Dividend USD 0.05
12/05/2013
11/29/2012
Dividend USD 0.1
12/07/2012
08/03/2012
Dividend USD 0.1
08/10/2012
11/08/2011
Dividend USD 0.1
11/16/2011
05/25/2011
Dividend USD 0.15
05/27/2011
11/30/2010
Dividend USD 0.65
12/14/2010
09/02/2010
Dividend USD 0.25
09/13/2010
05/11/2010
Dividend USD 0.1
05/27/2010
--
Dividend USD 1
12/08/2009
--
Dividend USD 0.25
08/21/2009
--
Dividend USD 0.1
05/27/2009
--
Dividend USD 1
12/10/2008
--
Dividend USD 0.25
10/31/2008
--
Dividend USD 0.25
07/24/2008
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DXR
Daxor Corporation is an investment company with medical instrumentation and biotechnology operations. The Company focuses on the development of the Blood Volume Analyzer (BVA) -100, an instrument that rapidly and accurately measures human blood volume. The Company’s instrument is used in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.The Company also owns the Daxor Oak Ridge Operations (DORO) facility in Oak Ridge, Tennessee. The semi-automated BVA provides blood volume measurements in human body for diagnosis and treatment in a range of medical and surgical conditions.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Daxor Corporation stock information, including AMEX:DXR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DXR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DXR stock methods without spending real money on the virtual paper trading platform.